Effect of propranolol on the myocardial contractility of normotensive and spontaneously hypertensive rabbits: Relationship of pharmacokinetics and pharmacodynamics
Tóm tắt
Myocardial contractility of normotensive and spontaneously hypertensive rabbits was determined following an iv bolus injection of propranolol HCl. Left ventricular pressure and dimension were used to calculate the contractility parameters of (dP/dt)
max
,maximum fiber shortening velocity V
cf
, and the slope of the end systolic pressure-end systolic volume line (ESP-ESV line). Hypertension was induced by a methoxamine HCl iv infusion which mimicked the cardiac effects seen in essential hypertension. Propanolol caused a significant decrease in all contractility parameters (p<0.05)within 15min after administration, with a peak effect occurring after 30–35 mins. The pharmacokinetics and pharmacodynamics of propranolol were fit using Hill's equation in conjunction with the concentration of drug in the theoretical effect compartment. The normotensive group of rabbits had a calculated EC
(50)
of 12.7 ng/ml, while the hypertensive group had an EC
50
of 6.9 ng/ml,indicating that the hypertensive rabbits were much more sensitive to the propranolol than the normotensive group. In addition, the normotensive group of rabbits demonstrated a much different pharmacokinetic-pharmacodynamic relationship than that of the hypertensive group, indicating that the hypertensive state of the animal has a significant effect upon the concentration-effect relationship.
Tài liệu tham khảo
E. Robin, C. Cowan, P. Puri, S. Ganguly, E. DeBoyrie, M. Martinez, T. Stock, and R. J. Bing. A comparative study of nitroglycerine and propranolol.Circulation 36:175–186 (1967).
R.H. Helfant, M. V. Herman and R. Gorlin, Abnormalities of the left ventricular contraction induced by beta blockade.Circulation 43:641–647 (1971).
L. B. Sheiner, D. R. Stanski, S. Vozeh, R. D. Miller, and J. Ham. Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to d-tubocurarine.Clin. Pharmacol. Ther. 25: 358–269 (1979).
W. A. Colburn. Simultaneous pharmacokinetic and pharmacodynamic modeling.J. Pharmacokin. Biopharm. 9:367–387 (1981).
N. H. G. Holford and L. B. Sheiner. Understanding the dose-effect relationship: Clinical application of pharmacokinetic-pharmacodynamic models.Clin. Pharmacokin. 6:429–453 (1981).
J. K-J Li. Regional ventricular function in myocardial ischemia. In S. Sideman and R. Beyar (eds.),Activation, Metabolism and Perfusion of the Heart, Martinus Nijhoff, The Hague, 1987.
E. Braunwald, J. Ros, and E. Sonenblick.Mechanism of Contraction of the Normal and Failing Heart, Little, Brown & Co., Boston, 1976.
E. Kwong and D. D. Shen. Versatile isocratic high-performance liquid chromatography assay for propranolol and its basic, neutral and acidic metabolites in biological fluids.J. Chromatogr. 414:365–397 (1987).
M. A. D. H. Schalekamp and G. J. Wenting. Mechanism of antihypertensive action of kertenserin in man.Br. Med. J. 287: 1300–1301 (1983).
F. Mahler, J. Covell, and J. Ross, Systolic pressure-diameter relations in normal conscious dog.Cardiovasc. Res. 9: 447–455 (1975).
K. Sagawa, H. Suga, A. A. Shoukas, and K. M. Bakalar. End-systolic pressure/volume ratio: A new index of ventricular contractility.Am. J. Cardiol. 40: 748–753 (1977).
A. Wellstein, D. Palm, G. G. Belz, and H. F. Pitschner. Receptor binding characteristics and pharmacokinetic properties as a tool for the prediction of clinical effect of beta blockers,Arzneim. Forsch. 35:2–6 (1985).